Unraveling dedifferentiation and metastasis traces in pancreatic ductal adenocarcinoma ductal cells: Insights from single-cell RNA sequencing analysis of ITGB4 and C19orf33

被引:2
作者
Asadzadeh, Zahra [1 ]
Hemmat, Nima [1 ]
Hassanian, Hamidreza [1 ,2 ]
Alizadeh, Nazila [1 ]
Mokhtarzadeh, Ahad [1 ]
Jafarlou, Mahdi [1 ]
Baradaran, Behzad [1 ,3 ,4 ]
机构
[1] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran
[4] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 371311, Iran
关键词
Pancreatic Ductal Adenocarcinoma; ScRNA-seq; 5-Fluorouracil; Oxaliplatin; System biology; FACTOR ACTIVATOR INHIBITOR; SMALL PEPTIDE; UP-REGULATION; CANCER; TUMOR; EXPRESSION; CYTOSCAPE; TYPE-2; H2RSP;
D O I
10.1016/j.prp.2023.155012
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Pancreatic Ductal Adenocarcinoma (PDAC) ranks among the most prevalent gastrointestinal malignancies, with risk factors including smoking, alcohol abuse, diabetes mellitus, obesity, age, family history, and genetic predisposition. Extensive research has focused on unraveling biomarkers and molecular intricacies associated with PDAC. Leveraging data from the Gene Expression Omnibus microarray and single-cell RNA sequencing datasets, our study identified ITGB4 and C19orf33 as potentially differentially expressed genes in PDAC samples when contrasted with non-malignant tissues. Notably, these genes exhibited a strong correlative expression pattern, primarily within ductal cells. Gene Expression Profiling Interactive Analysis corroborated our findings, further confirming the correlation between ITGB4 and C19orf33. Additionally, we conducted experiments involving two pivotal PDAC-related cell lines, MIA PaCa-2 and PANC-1, treated with oxaliplatin and 5-Fluorouracil. We also assessed the expression of these candidate genes in PDAC samples in comparison to adjacent normal tissues. Our findings revealed that C19orf33 is upregulated in PDAC samples, and treatment of PDAC cells with chemotherapeutic agents led to a correlated decrease in the expression of both ITGB4 and C19orf33. These co-expressed and correlated genes are implicated in relevant signaling pathways, suggesting shared biological activities that may contribute to the promotion of metastasis within malignant ductal cells. This study identifies ITGB4 and C19orf33 as key genes potentially shedding light on the molecular mechanisms driving tumorigenesis and metastasis in PDAC. These genes hold promise as potential diagnostic and therapeutic targets, offering valuable insights into the management of this challenging disease.
引用
收藏
页数:12
相关论文
共 44 条
  • [21] A single-cell type transcriptomics map of human tissues
    Karlsson, Max
    Zhang, Cheng
    Mear, Loren
    Zhong, Wen
    Digre, Andreas
    Katona, Borbala
    Sjoestedt, Evelina
    Butler, Lynn
    Odeberg, Jacob
    Dusart, Philip
    Edfors, Fredrik
    Oksvold, Per
    von Feilitzen, Kalle
    Zwahlen, Martin
    Arif, Muhammad
    Altay, Ozlem
    Li, Xiangyu
    Ozcan, Mehmet
    Mardonoglu, Adil
    Fagerberg, Linn
    Mulder, Jan
    Luo, Yonglun
    Ponten, Fredrik
    Uhlen, Mathias
    Lindskog, Cecilia
    [J]. SCIENCE ADVANCES, 2021, 7 (31):
  • [22] Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
    Kawaguchi, T
    Qin, L
    Shimomura, T
    Kondo, J
    Matsumoto, K
    Denda, K
    Kitamura, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) : 27558 - 27564
  • [23] Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment
    Le Large, Tessa Y. S.
    Prado, Mireia Mato
    Krell, Jonathan
    Bijlsma, Maarten F.
    Meijer, Laura L.
    Kazemier, Geert
    Frampton, Adam E.
    Giovannetti, Elisa
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (07) : 733 - 736
  • [24] ITGB4 is a novel prognostic factor in colon cancer
    Li, Meng
    Jiang, Xia
    Wang, Guiqi
    Zhai, Congjie
    Liu, Ying
    Li, Hongyan
    Zhang, Yan
    Yu, Weifang
    Zhao, Zengren
    [J]. JOURNAL OF CANCER, 2019, 10 (21): : 5223 - 5233
  • [25] Overcoming drug resistance in pancreatic cancer
    Long, Jiang
    Zhang, Yuqing
    Yu, Xianjun
    Yang, Jingxuan
    LeBrun, Drake G.
    Chen, Changyi
    Yao, Qizhi
    Li, Min
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (07) : 817 - 828
  • [26] 5-Fluorouracil: Mechanisms of action and clinical strategies
    Longley, DB
    Harkin, DP
    Johnston, PG
    [J]. NATURE REVIEWS CANCER, 2003, 3 (05) : 330 - 338
  • [27] Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library
    Lopez-Romero, Pedro
    [J]. BMC GENOMICS, 2011, 12
  • [28] Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI5-FU plus mitomycin in inoperable pancreatic cancer
    Maisey, N
    Chau, I
    Cunningham, D
    Norman, A
    Seymour, M
    Hickish, T
    Iveson, T
    O'Brien, M
    Tebbutt, N
    Harrington, A
    Hill, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) : 3130 - 3136
  • [29] Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma
    Masugi, Y.
    Yamazaki, K.
    Emoto, K.
    Effendi, K.
    Tsujikawa, H.
    Kitago, M.
    Itano, O.
    Kitagawa, Y.
    Sakamoto, M.
    [J]. LABORATORY INVESTIGATION, 2015, 95 (03) : 308 - 319
  • [30] Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway
    Meng, Xiangli
    Liu, Peng
    Wu, Yunhao
    Liu, Xinlu
    Huang, Yinpeng
    Yu, Boqiang
    Han, Jiahong
    Jin, Haoyi
    Tan, Xiaodong
    [J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2020, 20 (01) : 106 - 116